NIH, FDA to tighten, review consulting rules as Congressional inquiry continues.
In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.
HHS lawyer tells of pressure to allow former NCI Director Richard Klausner to receive $40,000 prize.
Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.
In Brief: ASCO awards career development grants.
Funding Opportunities listed.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
